{"id":48324,"date":"2022-09-13T19:01:47","date_gmt":"2022-09-13T17:01:47","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/"},"modified":"2022-09-13T19:01:47","modified_gmt":"2022-09-13T17:01:47","slug":"auria-the-future-of-breast-health-assessment-now-available-for-at-home-use","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/","title":{"rendered":"Auria\u2122, the future of breast health assessment now available for at-home use"},"content":{"rendered":"
\n

FAYETTEVILLE, Ark.–(BUSINESS WIRE)–Namida Lab, the world leader in tear-based diagnostics, today announced the launch of Auria\u2122, a first-of-its-kind breast health assessment test. Backed by physicians and more than a decade of research and clinical trials, Auria\u2122 is now available for women, ages 33-85 with an average risk of developing breast cancer, regardless of their breast tissue density, to encourage breast health screening. Auria\u2122 identifies protein biomarkers related to breast abnormalities through the power of tears.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nCurrently, 1 in 8 U.S. women will develop invasive breast cancer throughout their lifetime<\/a>. National mammography screening programs have sufficiently reduced breast cancer-related mortality. However, only 50% of women eligible for screening comply<\/a>, with those under the age of 45 struggling the most to meet the yearly recommendations. Namida Lab is bringing a resource to market that lowers the screening<\/a> barriers and increases education and support around breast health.\n<\/p>\n

\n\u201cWith Auria\u2122, the idea is to more broadly apply the technology so that we can screen more people. The easiest, most straightforward way of changing the course of the disease is to find it early,\u201d says Dr. Steve Harms, an internationally recognized breast imaging specialist.\n<\/p>\n

\nThe Auria\u2122 at-home test provides a personalized score and classification which corresponds to a level of urgency on when to schedule a screening mammogram. Auria customers also have the unique opportunity to schedule a one-on-one consultation with a breast health specialist to review their test results and ask any questions they may have related to their overall breast health. The goal is to encourage customers to take control of their breast health.\n<\/p>\n

\nThe inventor of Auria\u2122, Dr. Anna Daily, an expert in protein biochemistry with numerous peer-reviewed publications and patents on tear-based diagnostic development said, \u201cThis technology has taken over a decade of research, development, and clinical studies made possible through collaborations with comprehensive breast health and cancer centers across the US. Identifying proteins related to breast abnormalities is only the beginning. Information from the community of Auria\u2122 customers will lay the groundwork for personalized breast health intelligence, leading to optimized diagnostic thresholds, as well as the potential for breast cancer diagnostic tests utilizing tears.\u201d\n<\/p>\n

\nThe COVID-19 pandemic caused broad disruptions in breast care, reducing mammography screening, and resulting in unknown impacts on long-term breast cancer mortality<\/a>. In alignment with the current White House cancer panel recommendations<\/a>, Namida Lab remains focused on increasing access to self-sampling for cancer screening.\n<\/p>\n

\n\u201cThe team at Namida Lab has been working through the pandemic to bring Auria\u2122 to market, to provide a means of assessing one\u2019s breast health conveniently at home. Successful clinical testing of Auria\u2122 has allowed us to expand our vision to develop widely accessible, inexpensive, and accurate tests for other cancers,\u201d says Omid Moghadam, CEO, and co-founder of Namida Lab, Inc.\n<\/p>\n

\nAuria is available for purchase online at https:\/\/auria.care\/<\/a>. As part of the purchase, customers are invited to set up their personalized breast health dashboard. The Auria\u2122 kit provides material and instructions for at-home tear sample collection. After collection, the included return packaging allows for timely delivery of the sample to be tested at Namida\u2019s high-complexity CLIA lab. The physician-reviewed results are delivered to the customer\u2019s online dashboard, where they are encouraged to request a consultation with a breast health specialist.\n<\/p>\n

\nAuria\u2122 is not a diagnostic test for breast cancer and is not intended to replace a screening mammogram. Auria is a high complexity, lab-developed test (LDT) that has been developed and validated following rigorous precision, accuracy, and validity standards set forth by CLIA and is available by prescription only. In addition to a certified high-complexity CLIA lab, Namida Lab also offers access to a nationwide physician network.\n<\/p>\n

\nAbout Namida Lab<\/span><\/b>\n<\/p>\n

\nNamida Lab Inc. is a product-stage biotechnology company specializing in the development and commercialization of proteomics tests. Namida operates a high complexity CLIA (Clinical Laboratory Improvement Amendments) certified lab in addition to a Research & Development Lab to create and validate screening and diagnostic tools utilizing the untapped power of tears. Focusing on the oncology space, covering screening and diagnostics, their team consists of prominent scientists and industry professionals to improve diagnostic testing and patient outcomes.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSaul Robles
\n
Senior Marketing Manager, Namida Lab, Inc.
\n
+1-479-334-2828
\n
saul@namidalab.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

FAYETTEVILLE, Ark.–(BUSINESS WIRE)–Namida Lab, the world leader in tear-based diagnostics, today announced the launch of Auria\u2122, a first-of-its-kind breast health assessment test. Backed by physicians and more than a decade of research and clinical trials, Auria\u2122 is now available for women, ages 33-85 with an average risk of developing breast cancer, regardless of their breast … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48324","6":"format-standard","7":"category-industry"},"yoast_head":"\nAuria\u2122, the future of breast health assessment now available for at-home use - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Auria\u2122, the future of breast health assessment now available for at-home use - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FAYETTEVILLE, Ark.–(BUSINESS WIRE)–Namida Lab, the world leader in tear-based diagnostics, today announced the launch of Auria\u2122, a first-of-its-kind breast health assessment test. Backed by physicians and more than a decade of research and clinical trials, Auria\u2122 is now available for women, ages 33-85 with an average risk of developing breast cancer, regardless of their breast ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-13T17:01:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220913006075\/en\/1570345\/21\/auria-brand-3x2.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Auria\u2122, the future of breast health assessment now available for at-home use\",\"datePublished\":\"2022-09-13T17:01:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/\"},\"wordCount\":717,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913006075\\\/en\\\/1570345\\\/21\\\/auria-brand-3x2.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/\",\"name\":\"Auria\u2122, the future of breast health assessment now available for at-home use - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913006075\\\/en\\\/1570345\\\/21\\\/auria-brand-3x2.jpg\",\"datePublished\":\"2022-09-13T17:01:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913006075\\\/en\\\/1570345\\\/21\\\/auria-brand-3x2.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220913006075\\\/en\\\/1570345\\\/21\\\/auria-brand-3x2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Auria\u2122, the future of breast health assessment now available for at-home use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Auria\u2122, the future of breast health assessment now available for at-home use - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/","og_locale":"en_US","og_type":"article","og_title":"Auria\u2122, the future of breast health assessment now available for at-home use - Pharma Trend","og_description":"FAYETTEVILLE, Ark.–(BUSINESS WIRE)–Namida Lab, the world leader in tear-based diagnostics, today announced the launch of Auria\u2122, a first-of-its-kind breast health assessment test. Backed by physicians and more than a decade of research and clinical trials, Auria\u2122 is now available for women, ages 33-85 with an average risk of developing breast cancer, regardless of their breast ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-13T17:01:47+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220913006075\/en\/1570345\/21\/auria-brand-3x2.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Auria\u2122, the future of breast health assessment now available for at-home use","datePublished":"2022-09-13T17:01:47+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/"},"wordCount":717,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913006075\/en\/1570345\/21\/auria-brand-3x2.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/","url":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/","name":"Auria\u2122, the future of breast health assessment now available for at-home use - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220913006075\/en\/1570345\/21\/auria-brand-3x2.jpg","datePublished":"2022-09-13T17:01:47+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220913006075\/en\/1570345\/21\/auria-brand-3x2.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220913006075\/en\/1570345\/21\/auria-brand-3x2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/auria-the-future-of-breast-health-assessment-now-available-for-at-home-use\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Auria\u2122, the future of breast health assessment now available for at-home use"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48324","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48324"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48324\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48324"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48324"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48324"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}